NewsEvents

Your Yourlocation: Home > Clinical analysis of tiotropium bromide(136310-93-5) combined with salmeterol /fluticasone propionate in the treatment of moderate to severe COPD

To explore the clinical efficacy of combination therapy in moderate to severe COPD patients. The study indicated that tiotropium bromide(136310-93-5) combined with salmeterol / fluticasone propionate in patients with moderate to severe COPD can improve the patients' respiratory function and quality of life. The article was published on 2015 04 "Journal of Baotou Medical College".

120 patients with stable COPD were randomly divided into two groups. The control group received salmeterol / fluticasone propionate alone, and the observation group received tiotropium bromide(136310-93-5) on the basis of the control group.

The FEV1, FEV1, FEV1 / FVC of the patients in the observation group were significantly improved after treatment, and there were significant differences between the two groups before and after treatment (P <0.05) (P <0.05). After treatment, the scores of each factor in the St. George's Respiratory Questionnaire (SGRQ) were significantly lower than those in the control group (P <0.05). The differences between the two groups were statistically significant (P <0.05).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved